Stalicla
STALICLA is a clinical stage biotech company focused on precision medicine for neurodevelopmental and neuropsychiatric disorders. Utilizing their DEPI platform, they leverage multiomics, patient data, and AI to identify biologically distinct subgroups within these disorders, enabling tailored treatment approaches. Their innovative methodology addresses the challenges of traditional drug development by providing precise, personalized treatment options, which have shown promising results in clinical validations. With a mature pipeline, including assets for Autism Spectrum Disorder and substance use disorders, STALICLA is positioned to revolutionize treatment outcomes in these areas.
Stalicla
STALICLA is a clinical stage biotech company focused on precision medicine for neurodevelopmental and neuropsychiatric disorders. Utilizing their DEPI platform, they leverage multiomics, patient data, and AI to identify biologically distinct subgroups within these disorders, enabling tailored treatment approaches. Their innovative methodology addresses the challenges of traditional drug development by providing precise, personalized treatment options, which have shown promising results in clinical validations. With a mature pipeline, including assets for Autism Spectrum Disorder and substance use disorders, STALICLA is positioned to revolutionize treatment outcomes in these areas.